ES2170172T3 - Procedimiento y composiciones para inhibir las proteina quinasas. - Google Patents

Procedimiento y composiciones para inhibir las proteina quinasas.

Info

Publication number
ES2170172T3
ES2170172T3 ES95941340T ES95941340T ES2170172T3 ES 2170172 T3 ES2170172 T3 ES 2170172T3 ES 95941340 T ES95941340 T ES 95941340T ES 95941340 T ES95941340 T ES 95941340T ES 2170172 T3 ES2170172 T3 ES 2170172T3
Authority
ES
Spain
Prior art keywords
sub
reduced
inhibit
compositions
procedure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95941340T
Other languages
English (en)
Inventor
Neill A Giese
Nathalie Lokker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
COR Therapeutics Inc
Original Assignee
COR Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by COR Therapeutics Inc filed Critical COR Therapeutics Inc
Application granted granted Critical
Publication of ES2170172T3 publication Critical patent/ES2170172T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

SE MUESTRA UN METODO PARA INHIBIR SELECTIVAMENTE UNA QUINASA, QUE SUPONE LA PUESTA EN CONTACTO DE UNA COMPOSICION QUE CONTIENE UNA QUINASA CON UNA MOLECULA DE LA FORUMULA (I) DONDE R{SUB,1} ES H, ALQUIL REBAJADO, O ACANOIL REBAJADO; R{SUB,2} ES H, ALQUIL REBAJADO, O ALCANOIL REBAJADO; R{SUB,3} Y R{SUB,4} JUNTOS REPRESENTAN UN ENLACE DOBLE CIS O -O- O CADA UNO DE R{SUB,3} Y R{SUB,4} REPRESENTA INDEPENDIENTEMENTE H O OR; R{SUB,5} ES =0,=S, O -H, -OR; R{SUB,6} Y R{SUB,7} JUNTOS REPRESENTAN UN ENLACE DOBLE O -0-O CADA UNO DE R{SUB,6} Y R{SUB,7} INDEPENDIENTEMENTE REPRESENTA H O OR; R{SUB,8} Y R{SUB,9} JUNTOS REPRESENTAN UN ENLACE DOBLE O -0- O CADA UNO DE R{SUB,8} Y R{SUB,9} INDEPENDIENTEMENTE REPRESENTA H O OR, Y CADA R REPRESENTA INDEPENDIENTEMENTE H, ALQUIL REBAJADO, O ALCANOIL REBAJADO.
ES95941340T 1994-10-28 1995-10-26 Procedimiento y composiciones para inhibir las proteina quinasas. Expired - Lifetime ES2170172T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/332,597 US5795910A (en) 1994-10-28 1994-10-28 Method and compositions for inhibiting protein kinases

Publications (1)

Publication Number Publication Date
ES2170172T3 true ES2170172T3 (es) 2002-08-01

Family

ID=23298937

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95941340T Expired - Lifetime ES2170172T3 (es) 1994-10-28 1995-10-26 Procedimiento y composiciones para inhibir las proteina quinasas.

Country Status (14)

Country Link
US (3) US5795910A (es)
EP (1) EP0788356B9 (es)
JP (1) JPH10508024A (es)
KR (1) KR970706812A (es)
CN (1) CN1165481A (es)
AT (1) ATE210439T1 (es)
AU (1) AU706621B2 (es)
CA (1) CA2203757A1 (es)
DE (1) DE69524628T2 (es)
DK (1) DK0788356T3 (es)
ES (1) ES2170172T3 (es)
PT (1) PT788356E (es)
TW (1) TW467743B (es)
WO (1) WO1996013259A2 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6699843B2 (en) * 1995-06-07 2004-03-02 Gilead Sciences, Inc. Method for treatment of tumors using nucleic acid ligands to PDGF
EP0871060A4 (en) * 1996-08-06 1999-12-08 Seiko Epson Corp LIQUID CRYSTAL DISPLAY AND ELECTRONIC EQUIPMENT USING THE SAME
WO2000009113A1 (en) * 1998-08-17 2000-02-24 Trout William E Use of zeranol to modulate reproductive cycles
US20030219427A1 (en) * 1998-08-18 2003-11-27 Allen Hamish J. TPL-2/COT kinase and methods of use
MXPA01005641A (es) * 1998-12-07 2003-07-14 Ecosmart Technologies Inc Metodo y composicion para el tratamiento de cancer usando aceites vegetales esenciales naturales.
JP2002533389A (ja) 1998-12-24 2002-10-08 ノーベーション ファーマシューティカルズ インコーポレーテッド ｍＲＮＡ安定性に影響する化合物およびそのための使用
AU781877B2 (en) * 1999-08-13 2005-06-16 Scripps Research Institute, The Methods and compositions useful for modulation of angiogenesis using protein kinase Raf and Ras
GB9925958D0 (en) * 1999-11-02 1999-12-29 Bundred Nigel J Therapeutic use
US7087608B2 (en) * 2000-03-03 2006-08-08 Robert Charles Atkins Use of PDGF receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy
JP2004292314A (ja) * 2000-12-14 2004-10-21 Chugai Pharmaceut Co Ltd ケラチノサイト増殖抑制剤
US6565864B2 (en) 2000-12-28 2003-05-20 Unilever Home & Personal Care Usa, A Division Of Conopco, Inc. Skin care product containing retinoids and phytoestrogens in a dual compartment package
EP1357807B1 (en) * 2001-02-09 2007-03-14 Unilever N.V. Food product comprising soy protein and statins
EP1450784A4 (en) * 2001-11-09 2005-02-09 Conforma Therapeutics Corp HSP90-INHIBITABLE ZEARALANOL COMPOUNDS AND METHOD FOR THEIR PREPARATION AND USE
FR2835252B1 (fr) 2002-01-25 2005-08-05 Seppic Sa Utilisation d'un compose inactivant la proteine kinase a dans une composition contenant un milieu cosmetiquement acceptable, pour eclaicir la peau
WO2003076424A1 (en) * 2002-03-08 2003-09-18 Eisai Co. Ltd. Macrocyclic compounds useful as pharmaceuticals
US7915306B2 (en) * 2002-03-08 2011-03-29 Eisai Co., Ltd. Macrocyclic compounds useful as pharmaceuticals
WO2003086334A1 (fr) * 2002-04-17 2003-10-23 Taisho Pharmaceutical Co., Ltd. Produit tonique pour la pousse de cheveux
US8853376B2 (en) 2002-11-21 2014-10-07 Archemix Llc Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
EP1608338A1 (en) * 2003-04-02 2005-12-28 Celator Technologies Inc. Pharmaceutical compositions containing active agents having a lactone group and transition metal ions
NZ546088A (en) 2003-08-27 2009-10-30 Ophthotech Corp Combination therapy for the treatment of ocular neovascular disorders using a PDGF antagonist and a VEGF antagonist
EP1794137A4 (en) * 2004-09-27 2009-12-02 Kosan Biosciences Inc SPECIFIC KINASE INHIBITORS
WO2007076358A1 (en) * 2005-12-23 2007-07-05 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
US7601852B2 (en) * 2006-05-11 2009-10-13 Kosan Biosciences Incorporated Macrocyclic kinase inhibitors
US8067412B2 (en) * 2006-08-11 2011-11-29 Universite De Strasbourg Macrocyclic compounds useful as inhibitors of kinases and HSP90
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
ES2670423T3 (es) 2007-07-25 2018-05-30 Eisai R&D Management Co., Ltd. Inhibidores de multicinasas para uso en el tratamiento de cáncer
JP5564431B2 (ja) 2007-10-29 2014-07-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 ゼアラレノンアナログ化合物ががんを処置する能力を予測する方法
EP2231635B1 (en) 2007-12-07 2014-03-19 Eisai R&D Management Co., Ltd. Intermediates and methods for making zearalenone macrolide analogs
US20110190237A1 (en) * 2008-01-15 2011-08-04 Nexgenix Pharmaceuticals Macrocyclic Prodrug Compounds Useful as Therapeutics
US20120189641A1 (en) 2009-02-25 2012-07-26 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
EP2401614A1 (en) 2009-02-27 2012-01-04 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
US8465912B2 (en) 2009-02-27 2013-06-18 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
CN101928700B (zh) * 2009-07-28 2012-05-02 北京恒宇视野生物科技有限公司 蛋白激酶pftk1单克隆抗体及其制备方法
CA2808866A1 (en) 2010-08-20 2012-02-23 The Hospital For Sick Children Compositions and methods for treatment of cystic fibrosis and diseases associated with aberrant protein cellular processing
US9896730B2 (en) 2011-04-25 2018-02-20 OSI Pharmaceuticals, LLC Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
WO2016196256A2 (en) 2015-06-04 2016-12-08 University Of North Carolina At Greensboro Non-aromatic difluoro analogues of resorcylic acid lactones

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3196019A (en) * 1964-04-06 1965-07-20 Purdue Research Foundation Anabolic and estrogenic compound and process of making
JPS6239558A (ja) * 1985-08-13 1987-02-20 Kanegafuchi Chem Ind Co Ltd α−シアノアクリル酸アミド誘導体
JPS6239523A (ja) * 1985-08-14 1987-02-20 Kanegafuchi Chem Ind Co Ltd 酵素阻害剤
JPS6242923A (ja) * 1985-08-19 1987-02-24 Kanegafuchi Chem Ind Co Ltd 酵素阻害剤
JPS6242925A (ja) * 1985-08-20 1987-02-24 Kanegafuchi Chem Ind Co Ltd 酵素阻害剤
US4842862A (en) * 1986-07-03 1989-06-27 International Minerals & Chemical Corp. Immunostimulating agents
GB9225396D0 (en) * 1992-12-04 1993-01-27 Sandoz Ltd Improvements in or relating to organic compounds

Also Published As

Publication number Publication date
PT788356E (pt) 2002-06-28
US5728726A (en) 1998-03-17
EP0788356B9 (en) 2002-10-02
WO1996013259A3 (en) 1996-08-01
US5795910A (en) 1998-08-18
US5674892A (en) 1997-10-07
CN1165481A (zh) 1997-11-19
TW467743B (en) 2001-12-11
DK0788356T3 (da) 2002-03-18
KR970706812A (ko) 1997-12-01
WO1996013259A2 (en) 1996-05-09
DE69524628D1 (de) 2002-01-24
MX9703113A (es) 1998-06-30
EP0788356A2 (en) 1997-08-13
ATE210439T1 (de) 2001-12-15
CA2203757A1 (en) 1996-05-09
JPH10508024A (ja) 1998-08-04
EP0788356B1 (en) 2001-12-12
DE69524628T2 (de) 2002-08-08
AU4278996A (en) 1996-05-23
AU706621B2 (en) 1999-06-17

Similar Documents

Publication Publication Date Title
ES2170172T3 (es) Procedimiento y composiciones para inhibir las proteina quinasas.
ES2062812T3 (es) Composicion detergente enzimatica y metodo para estabilizar enzimas.
DE69813898D1 (de) Substituierte porphyrinen
DE3482107D1 (de) Zementzusammensetzungen und zementierungsverfahren in oelgebieten.
DE3586959D1 (de) Desinfektionsverfahren sowie zusammensetzung dafuer.
DK325789D0 (da) Fremgangsmaade til forbedring af lagerstabiliteten af amidperoxysyrer og detergentsammensaetning omfattende disse
MX9203373A (es) 3-amino-1-hidroxi-propan-1,1-difosfonato disodico y composiciones farmaceuticas que lo contienen.
DK0791046T3 (da) Detergentsammensætninger, der indeholder lipase og protease
DE3584143D1 (de) Gelenkprothese.
DE69414723D1 (de) Lyophilisierte stammzellenfaktor formulierungen
NO163722C (no) Prefabrikert sett for fremstilling av sigaretter, fremgangsmaate og anvendelse av settet.
ES556659A0 (es) Un procedimiento para preparar derivados de 1-aminobut-3-eno
DK249680A (da) Fremgangsmaade til fremstilling af 4-substituerede 3-hydroxy-3-pyrrolin-2,5-dioner
DE3583035D1 (de) Ableitventil.
NO179054C (no) Tetningsmiddel for ventilstamme for å hindre flyktige avgivelser
DE3579861D1 (de) Haertbare organopolysiloxanzusammensetzungen.
DK90085D0 (da) Laaseindretning til olieplatforme
FI840463A (fi) Vissa bensazokinon- och bensazoninonderivat.
DK152849C (da) Koerbar sporunderstopningsmaskine, isaer maskine til samtidig nivellering og opretning af sporlegemers skinner.
DE3586006D1 (de) Verfahren und zusammensetzungen zur expression von bti-endo-toxin.
YU45719B (sh) Postopek za pripravo mešano substituiranih enantiomerno čistih 1,2-diacil-sn-gli cero-3-fosfoholinov in 1,2-di-acil-sn-glicero-3-fosfoetanolaminov
DE3480934D1 (de) Zusammensetzungen von polyamid-gummi-mischungen.
DE68917777D1 (de) Enzymatische Waschmittelzusammensetzung.
NO851608L (no) Sammensetning og fremgangsmaate for endring av permeabiliteten til en underjordisk formasjon.
DE3583843D1 (de) Verfahren zum zementieren von bohrloechern und zusammensetzungen.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 788356

Country of ref document: ES